Contraception
Conditions
Keywords
postpartum, contraception, postplacental IUD, intrauterine devices
Brief summary
This study is a randomized controlled trial comparing 6 month usage rates of the levonorgestrel-releasing intrauterine device (LNG-IUD) when inserted postplacentally after vaginal delivery or delayed placement at 6-8 weeks postpartum. Given the high rate of unintended pregnancy in the United States, particularly in postpartum women, there is a need for reliable, effective, long-term contraception such as the IUD in postpartum women. Postplacental insertion of intrauterine contraception would help to address this need. The primary hypothesis of this study is that use of the LNG-IUD at 6 months after vaginal delivery will be higher in women who have immediate postplacental insertion as compared to delayed insertion 6-8 weeks following delivery.
Detailed description
The United States (US) has the highest unintended pregnancy rate of any developed country. Of the 6.4 million pregnancies in the US each year, almost half are unintended (49%). Roughly half of these (22% of all pregnancies) result in unintended births, while 20% of all pregnancies result in abortion. Postpartum women are particularly susceptible, with an unintended pregnancy rate of 10%-44% in the first year postpartum. These unintended pregnancies occur despite the recommendation that a contraceptive method be selected prior to hospital discharge. Given the high rate of unintended pregnancy in the United States, particularly in postpartum women, there is a need for reliable, effective, long-term contraception such as the IUD in postpartum women. Postplacental insertion of intrauterine contraception would help to address this need. The IUD is a highly effective but underused method of postpartum contraception. Although the expulsion rate in postplacental insertion is higher than interval insertion, the benefits of highly effective contraception available immediately after delivery may outweigh the risks of expulsion. To date, there have been no randomized trials of postplacental insertion of the LNG-IUD in the United States. One pilot study in the United States of 20 subjects who received an ultrasound-guided postplacental insertion of the LNG-IUD showed an acceptable expulsion rate of 10% and no infections over a 10-week follow-up, thus making postplacental insertion of LNG-IUD safe for further study. This study is a randomized controlled trial comparing 6 month usage rates of the levonorgestrel-releasing intrauterine device (LNG-IUD) when inserted postplacentally after vaginal delivery or delayed placement at 6-8 weeks postpartum. One hundred sixty-eight women receiving prenatal care at Magee-Womens Hospital, Pittsburgh, PA, who are interested in using the LNG-IUD for contraception will be enrolled during their pregnancy. The IUD will be inserted within 10 minutes after delivery of the placenta in women randomized to immediate insertion. Delayed IUD insertion will be performed at the first postpartum visit in 6-8 weeks. All subjects will follow up in person at 6-8 weeks and 6 months after delivery. A telephone interview will occur at 3 months after delivery for all subjects. Subjects who are not eligible for insertion due to post-randomization ineligibility criteria will be referred to their primary gynecologist or midwife for delayed IUD placement. They will be contacted by phone at 3 and 6 months to assess quality of life, contraceptive usage, and unintended pregnancy rates.
Interventions
levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
Sponsors
Study design
Eligibility
Inclusion criteria
* Age greater than or equal to 18 years * Greater than or equal to 24 0/7 weeks pregnant at time of enrollment * Anticipates undergoing a vaginal delivery * Desires to use the LNG-IUD (Mirena) for postpartum contraception * Willing and able to sign an informed consent in English * Willing to comply with the study protocol
Exclusion criteria
* Planning to undergo a scheduled cesarean section * Allergy to either polyethylene or levonorgestrel or other contraindications to use of the LNG-IUD * Exposure to or treatment for gonorrhea, chlamydia, or trichomoniasis during the pregnancy * Presence of one or more leiomyomata greater than 3 centimeters in diameter * Uterine anomaly (other than a repaired septate uterus) * Current cervical cancer or carcinoma in-situ * Desires repeat pregnancy within one year of delivery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| IUD Usage Rate at 6 Months | 6 months after delivery | Usage rate of the LNG-IUD at 6 months after delivery |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of Women Who Are Able to Have the LNG-IUD Placed Postplacentally and Are Not Excluded From Placement | 6 months |
| Follow-up Rates for Delayed Insertion of LNG-IUD | 6 months |
| Expulsion Rates of Post-placental and Delayed Insertion of the LNG-IUD Using Clinical Exam and Ultrasonography | 6 months |
| Safety of Postplacental Insertion of the LNG-IUD as Measured by Infection Rates | 6 months |
| Rates of Follow-up and Unintended Pregnancy Rates for Subjects Who Are Excluded From Postpartum Insertion | 6 months |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Immediate Postplacental IUD Insertion immediate postplacental IUD insertion
Levonorgestrel-releasing IUD (Mirena): levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years | 51 |
| Delayed IUD Insertion (6-8 Weeks After Delivery) delayed IUD insertion (6-8 weeks after delivery)
Levonorgestrel-releasing IUD (Mirena): levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years | 51 |
| Total | 102 |
Baseline characteristics
| Characteristic | Immediate Postplacental IUD Insertion | Delayed IUD Insertion (6-8 Weeks After Delivery) | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 51 Participants | 51 Participants | 102 Participants |
| Age, Continuous | 25.4 years STANDARD_DEVIATION 5.3 | 24.7 years STANDARD_DEVIATION 5.2 | 25.1 years STANDARD_DEVIATION 5.2 |
| Received IUD per protocol Did not receive IUD per protocol | 1 participants | 5 participants | 6 participants |
| Received IUD per protocol Received IUD per protocol | 50 participants | 46 participants | 96 participants |
| Region of Enrollment United States | 51 participants | 51 participants | 102 participants |
| Sex: Female, Male Female | 51 Participants | 51 Participants | 102 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 3 / 51 | 0 / 51 |
| serious Total, serious adverse events | 1 / 51 | 0 / 51 |
Outcome results
IUD Usage Rate at 6 Months
Usage rate of the LNG-IUD at 6 months after delivery
Time frame: 6 months after delivery
Population: IUD use at 6 months, lost to follow-up counted as failures
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Postplacental IUD Insertion | IUD Usage Rate at 6 Months | 43 participants |
| Delayed IUD Insertion | IUD Usage Rate at 6 Months | 39 participants |
Expulsion Rates of Post-placental and Delayed Insertion of the LNG-IUD Using Clinical Exam and Ultrasonography
Time frame: 6 months
Population: The population only includes women who received IUDs at the specified timepoint. Only 50/51 women in the postplacental group had a successful IUD insertion postplacentally. Only 46 of 51 women in the delayed group returned for a delayed IUD insertion.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Postplacental IUD Insertion | Expulsion Rates of Post-placental and Delayed Insertion of the LNG-IUD Using Clinical Exam and Ultrasonography | 12 participants |
| Delayed IUD Insertion | Expulsion Rates of Post-placental and Delayed Insertion of the LNG-IUD Using Clinical Exam and Ultrasonography | 2 participants |
Follow-up Rates for Delayed Insertion of LNG-IUD
Time frame: 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Postplacental IUD Insertion | Follow-up Rates for Delayed Insertion of LNG-IUD | 46 participants |
Proportion of Women Who Are Able to Have the LNG-IUD Placed Postplacentally and Are Not Excluded From Placement
Time frame: 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Postplacental IUD Insertion | Proportion of Women Who Are Able to Have the LNG-IUD Placed Postplacentally and Are Not Excluded From Placement | 50 participants |
Rates of Follow-up and Unintended Pregnancy Rates for Subjects Who Are Excluded From Postpartum Insertion
Time frame: 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Postplacental IUD Insertion | Rates of Follow-up and Unintended Pregnancy Rates for Subjects Who Are Excluded From Postpartum Insertion | 2 participants |
| Delayed IUD Insertion | Rates of Follow-up and Unintended Pregnancy Rates for Subjects Who Are Excluded From Postpartum Insertion | 11 participants |
Safety of Postplacental Insertion of the LNG-IUD as Measured by Infection Rates
Time frame: 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Postplacental IUD Insertion | Safety of Postplacental Insertion of the LNG-IUD as Measured by Infection Rates | 1 participants |
| Delayed IUD Insertion | Safety of Postplacental Insertion of the LNG-IUD as Measured by Infection Rates | 1 participants |